3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Tumor-Agnostic
1
Other neoplasm
1
Lymphoid
1
Head & Neck
1
Breast
1
Conditions
Precancerous Conditions
1
Esophageal Neoplasms
1
Barrett Esophagus
1
Interventions
Whole-Body Irradiation
4
Sulindac
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
fludarabine phosphate
3
Selenium
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Cetuximab
3
Biopsy
3
Tacrolimus
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Polymerase Chain Reaction
2
Oxycodone
2
Mycophenolic Acid
2
Melphalan
2
Gene Expression Profiling
2
Etoposide
2
Darbepoetin alfa
2
Cyclosporine
2
Cyclophosphamide
2
Cisplatin
2
Busulfan
2
Aspirin
2
Aminolevulinic Acid
2
Albumin-Bound Paclitaxel
2
vandetanib
1
soybean oil, phospholipid emulsion
1
ruxolitinib
1
polyphenon E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Esomeprazole
×
Other neoplasm
×
Clear all
NCT00357682
2025-05-01
AspECT
University of Oxford
Phase 3
Completed
2,557 enrolled
17 charts